Press Release
Liquid Biopsy Market Surges with 16.34% CAGR Amid Precision Healthcare Demand
Date: April 2, 2026, Pune
The Global Liquid Biopsy Market is entering a phase of robust expansion, with its valuation projected to reach approximately USD 7.25 billion in 2025 and anticipated to surge to nearly USD 30.24 billion by 2035. This remarkable growth reflects the increasing adoption of non-invasive diagnostic technologies, particularly in oncology and personalized medicine.
The market is expected to register a strong CAGR of around 16.34% during the forecast period (2025–2035), highlighting significant momentum fueled by technological advancements, rising healthcare investments, and expanding applications in early cancer detection, treatment monitoring, and recurrence tracking.
For a free sample of the report, please contact us here:
https://globaldatarouteanalytics.com/report/1169/liquid-biopsy-market/download
Liquid biopsy technologies, including Next-Generation Sequencing (NGS), digital PCR (dPCR), PCR-based methods, microarrays, and CRISPR-based diagnostics, are transforming the diagnostic landscape. These innovations enable real-time, non-invasive analysis of biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and cell-free RNA (cfRNA), offering improved accuracy and patient convenience.
The growing preference for blood-based testing, along with advancements in multi-sample analysis including urine, saliva, and feces, is further accelerating market adoption across healthcare settings.
For any inquiry related to this report, please click here:
https://globaldatarouteanalytics.com/report/1169/liquid-biopsy-market/inquiry
From a strategic perspective, the industry is witnessing increasing collaboration between biotechnology companies, diagnostic laboratories, and healthcare providers. These partnerships aim to enhance diagnostic precision, optimize treatment outcomes, and expand access to early-stage disease detection solutions.
Despite strong growth prospects, the market faces competitive pressures. High industry rivalry, coupled with the presence of alternative diagnostic methods such as traditional tissue biopsies and imaging techniques, continues to shape market dynamics. Additionally, buyers such as hospitals and research institutions exert significant influence due to increasing demand for cost-effective and accurate diagnostic solutions.
For discounts related to this report, explore here:
https://globaldatarouteanalytics.com/report/1169/liquid-biopsy-market/discount
Regionally, North America and Europe remain key contributors due to advanced healthcare infrastructure and strong R&D investments, while Asia Pacific—particularly China and India—is emerging as a high-growth region driven by expanding healthcare access and rising awareness.
Key players operating in the market include Guardant Health, Inc., Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Personalis, Inc., Foundation Medicine, Inc., NeoGenomics Laboratories, Biocept, Inc., and Exosome Sciences Inc., all of which are actively investing in innovation, strategic partnerships, and product development to strengthen their market position.
About Global Data Route Analytics
Global Data Route Analytics is a market research and consulting firm that provides businesses with data analysis, market forecasts, and tailored reports across various industries. The company uses advanced data analysis techniques, proprietary data, and an expert team to help clients understand market trends, make informed decisions, and develop strategies. They focus on delivering customized solutions, competitive intelligence, and growth strategies to help businesses succeed in their respective markets.
Media Contact:
Srushti Tungar
Global Data Route Analytics